Mashup Score:7
ASCO Connection# ASCO20
Mashup Score:4
meetinglibrary.asco.orgMeeting Library | Meeting Library - 1 week
Mashup Score:4
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2021 American Society of Clinical Oncology (ASCO). All Rights Reserved...
-
Patterns of Twitter use among trainees in hematology-oncology related areas - Miguel Gonzalez Velez @NarjustDumaMD @DanielCabrera @AMarshallMD @DrAttai @DrMarkham @Rfonsi1 J Clin Oncol 38: 2020 (suppl; abstr 11041) #ASCO20 https://t.co/gQgx39RtLv #socialoncology #MedEd #COSMO21 https://t.co/gQgx39RtLv - view on twitter
e19332 Background: US MM-6 is investigating iCT from parenteral V-based induction to all-oral I-lenalidomide-dexamethasone (IRd) with the aim of increasing proteasome inhibitor (PI)-based treatment...
-
Long-term proteasome inhibition in US community multiple myeloma Pts following in-class transition (iCT) from parenteral bortezomib to oral ixazomib: Updated real-world data from US MM-6 [May 25, 2020] Girnius et al. #ASCO20 Abst e19332 https://t.co/yu2uHai4Xx #NCT03173092 #mmsm - view on twitter
e21664 Background: Hyperprogressive disease (HPD) is a new pattern of progressión during immunotherapy and is described as an acceleration of tumor growth during treatment...
-
Hyperprogressive disease during treatment w/ [mono] immune checkpoint inhibitors in Pts w/ advanced NSCLC [May 25, 2020] Pablo Ayala de Miguel et al. Abs e21664 #ASCO20 https://t.co/DKpS8DSYTD #lcsm #ImmunoOnc 9/104 HPD. All in <2 mon. MVA >= 2 met sites (HR 8.59, p = 0.026) - view on twitter
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2021 American Society of Clinical Oncology (ASCO). All Rights Reserved...
-
Molecular alterations w/ hyperprogression in lung cancer Pts Tx'd w/ immune checkpoint inhibitors in a large health system - Tadesse et al. Abst e15082 #ASCO20 https://t.co/b8M7tBHYGO #ImmunoOnc #lcsm Only STK11/LKB1 mut assoc w/ HP (P =< 0.0001) w/ 5/6 STK11 ICI Tx'd showing HP https://t.co/b8M7tBHYGO - view on twitter
e19332 Background: US MM-6 is investigating iCT from parenteral V-based induction to all-oral I-lenalidomide-dexamethasone (IRd) with the aim of increasing proteasome inhibitor (PI)-based treatment...
-
Long-term proteasome inhibition in US community multiple myeloma Pts following in-class transition (iCT) from parenteral bortezomib to oral ixazomib: Updated real-world data from US MM-6 [May 25, 2020] Girnius et al. #ASCO20 Abst e19332 https://t.co/yu2uHai4Xx #NCT03173092 #mmsm https://t.co/yu2uHai4Xx - view on twitter
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2021 American Society of Clinical Oncology (ASCO). All Rights Reserved...
-
Molecular alterations w/ hyperprogression in lung cancer Pts Tx'd w/ immune checkpoint inhibitors in a large health system - Tadesse et al. Abst e15082 #ASCO20 https://t.co/b8M7tBHYGO #ImmunoOnc #lcsm Only STK11/LKB1 mut assoc w/ HP (P =< 0.0001) w/ 5/6 STK11 ICI Tx'd showing HP https://t.co/b8M7tBHYGO - view on twitter
Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary...
-
MT @OncLive @ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting @DrSGraff @SarahCannonDocs @DrChoueiri @DanaFarber @StephenVLiu @Georgetown @mtmdphd @Aurora_Cancer @GIcancerDoc @MayoClinic https://t.co/bsdxZE3p35 #ASCO20 - view on twitter
More coverage:
#asco20
This randomized clinical trial assesses the efficacy and safety of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced squamous...
-
#OncoAlert Results from the phase III RATIONALE 307 trial of tislelizumab (anti-PD1) plus 1L chemo vs chemo alone in squamous NSCLC @JAMAOnc. Interim results were presented at #ASCO20. With full results, tislelizumab was approved in China 1/13/21. #LCSM https://t.co/nEBzzuIaju - view on twitter
In the United States, many cancer centers advertise their clinical services directly to the public. Although there are potential public benefits from such advertising,...
-
Direct-to-Consumer Advertising for Cancer Centers and Institutes: Ethical Dilemmas and Practical Implications [May 7, 2020] @FayUCCancerCr et al. @ASCO #ASCO20 Education Book e207-e217 https://t.co/c3M9A6bFr8 - view on twitter
More coverage:
#asco20
Dr. Emil Lou and Dr. Muhammad Shaalan Beg, of ASCO’s Social Media Working Group, explore the role and reach of Twitter and Instagram during...
.@ShaalanBeg and I shared some thoughts on the @ASCO #ASCOconnection 11/16/20 on: The Landscape of #ASCO20: Evolution and Validation of the Role of Social Media in a New Virtual World #COSMO21 #COSMOnc #SoMe https://t.co/r9Kort36rz https://t.co/r9Kort36rz - view on twitter